Study in Patients With Mild to Moderate Psoriasis

Inclusion Criteria: * Subjects diagnosed with mild to moderate psoriasis as defined by the clinician, * Has a Psoriasis Area and Severity Index{PASI} of less than 20, * Male or female subjects, * Aged between 18-60 years of age, * Non-pregnant female and must agree to use adequate method of contraception during the study, * Is capable of giving written informed consent prior to study entry, * Be willing to refrain from taking dietary supplements or other foods that contain fermented live bacteria within 1 month prior to treatment and during the study, * Have not participated in a clinical drug study or used an investigational new drug during the past previous 30 days, * Clinical Chemistry and haematology results from Visit 1 are within normal limits, * Be willing to refrain from using any topical psoriactic cream 2 weeks prior to treatment and during the study. Exclusion Criteria: * Are less than 18 years of age, and not more than 60 years of age, * History of sensitivity to lactose \[eg, lactose intolerance\] or other dairy products, * History of consumption of probiotics,1 month prior to treatment, * Being treated with steroids 2 weeks prior to entry, Diseases of the gastrointestinal tract,liver,pancreas and biliary tree\[eg;gastritis,symptomatic gall stones,duodenal ulcer,gastroenteritis,diverticulitis.\] Exceptions include haemorrhoids,hiatus hernia and asymptomatic gall stones. * History of major gastric,hepatic,pancreatic or intestinal surgery or perforation,excluding cholescystectomy,appendicectomy,haemorrhoidectomy or polypectomy. * Recent unexplained rectal bleeding and/or significant unexplained weight loss. * Antibiotic use within one month prior to Visit 1. have a significant acute or chronic coexisting illness{cardiovascular,gastrointestinal,immunological}or a condition, which contraindicates,in the investigators judgement entry to the study. * Patients with Diabetes Mellitus. * Individuals who, in the opinion of the investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the trial. * Subjects currently receiving treatment involving experimental drugs. * If a subjects has been in a recent experimental trial,must be not less than 30 days prior to this study. * Have a concomitant end stage organ disease eg; cardiovascular,hepatic,pulmonary,renal,which , in the Investigators judgement,contraindicates participation in the study. * Have a history of malignancy in the past 5 years with the exception of Basal Cell Carcinoma. * Evidence of alcohol or drug abuse. * Evidence of unstable forms of psoriasis,including guttate, erthrodermic , exfoliative or pustular psoriasis. * Evidence of other inflammatory skin disease that may confound the evaluation of psoriasis. * Has had systematic antipsoriatic treatment or PUVA therapy within the previous 4 weeks. * Subject who has had UVB therapy with the previous 2 weeks. * If the subjects scores \>20% on the PASI.